Abiopharma

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Net Asset Value(s)

Mineros S.A. Achieves Major Milestone With Porvenir Project Development

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Clene to Present at Upcoming May Conferences

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Fleet Launch Customer NetJets Takes Delivery of First Three Cessna Citation Ascend Midsize Business Jets